Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice
Open Access
- 27 December 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (2), 762-767
- https://doi.org/10.1073/pnas.1013067108
Abstract
Duchenne muscular dystrophy (DMD) is caused by mutations in dystrophin and the subsequent disruption of the dystrophin-associated protein complex (DAPC). Utrophin is a dystrophin homolog expressed at high levels in developing muscle that is an attractive target for DMD therapy. Here we show that the extracellular matrix protein biglycan regulates utrophin expression in immature muscle and that recombinant human biglycan (rhBGN) increases utrophin expression in cultured myotubes. Systemically delivered rhBGN up-regulates utrophin at the sarcolemma and reduces muscle pathology in the mdx mouse model of DMD. RhBGN treatment also improves muscle function as judged by reduced susceptibility to eccentric contraction-induced injury. Utrophin is required for the rhBGN therapeutic effect. Several lines of evidence indicate that biglycan acts by recruiting utrophin protein to the muscle membrane. RhBGN is well tolerated in animals dosed for as long as 3 months. We propose that rhBGN could be a therapy for DMD.Keywords
This publication has 52 references indexed in Scilit:
- Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophinJournal of Cell Science, 2010
- Functional Substitution by TAT-Utrophin in Dystrophin-Deficient MicePLoS Medicine, 2009
- Sarcolemma-localized nNOS is required to maintain activity after mild exerciseNature, 2008
- IRES-Mediated Translation of Utrophin A Is Enhanced by Glucocorticoid Treatment in Skeletal Muscle CellsPLOS ONE, 2008
- Biglycan binds to α‐ and γ‐sarcoglycan and regulates their expression during developmentJournal of Cellular Physiology, 2006
- Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOSThe FASEB Journal, 2006
- Transient up-regulation of biglycan during skeletal muscle regeneration: delayed fiber growth along with decorin increase in biglycan-deficient miceDevelopmental Biology, 2004
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003
- Biglycan and Decorin Bind Close to the N-terminal Region of the Collagen VI Triple HelixPublished by Elsevier BV ,2001
- Full‐length and short forms of utrophin, the dystrophin‐related proteinFEBS Letters, 1995